Ascelia Pharma AB (publ) (ACE) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ascelia Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:06.017 Welcome everyone to the webcast for Acelia Pharma's Q4 report for 2025. 00:00:06.600 -- 00:00:10.783 On this call, we will be making forward-looking statements. 00:00:10.926 -- 00:00:15.873 On today's call, we will start with an overview of Acelia Pharma, recent key events, 00:00:15.873 -- 00:00:19.799 and then head into the portfolio update before moving on to financials and priorities 00:00:19.799 -- 00:00:24.820 ahead. After the presentation, we will open up for questions as usual. 00:00:24.820 -- 00:00:27.584 I'm Magnus Corfertsen, CEO of Acelia Pharma. 00:00:27.584 -- 00:00:32.872 And with me today, I have Julie Varas Brogren, Deputy CEO, Andreas Norlin, Chief Scientific 00:00:32.872 -- 00:00:36.057 Officer, and Anton Hansson, CFO. 00:00:36.057 -- 00:00:41.866 I'm pleased to welcome Anton to his first quarterly call as Chief Financial Officer. 00:00:41.866 -- 00:00:45.592 This will also be the last quarterly call with Julie, as she will be moving on to new 00:00:45.592 -- 00:00:49.315 opportunities, as we announced a few weeks ago. 00:00:50.167 -- 00:00:55.054 At Acelia Pharma, we identify, develop, and commercialize novel drugs that address unmet 00:00:55.054 -- 00:00:59.160 medical needs across rare cancer conditions. 00:00:59.160 -- 00:01:03.864 We're based in Malmö, Sweden, and are listed on NASDAQ Stockholm. 00:01:03.907 -- 00:01:09.195 We have two drugs in our pipeline. Orviglans is a diagnostic drug that is now under FDA 00:01:09.195 -- 00:01:12.941 review with a Biduva date of July 3rd this year. 00:01:12.941 -- 00:01:16.407 We will spend the majority of this call talking about Orviglans. 00:01:16.407 -- 00:01:21.255 Oncoral is a patented tablet formulation of ibuprofen with encouraging results in phase 00:01:21.255 --...